Cargando…
Ectopic Expression of Sortilin 1 (NTR-3) in Patients with Ovarian Carcinoma
Gene expression profiling of ovarian carcinoma tissues has shown an increase of four-fold expression of SORT1 gene. Sortilin 1 (NTR-3) is a 95–100 kDa protein normally expressed in heart, brain, placenta, skeletal muscle, spinal cord, thyroid, and testis. However, its expression has never been repor...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Avicenna Research Institute
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3558127/ https://www.ncbi.nlm.nih.gov/pubmed/23407681 |
_version_ | 1782257376330514432 |
---|---|
author | Hemmati, Shayda Zarnani, Amir Hassan Mahmoudi, Ahmad Reza Sadeghi, Mohammad-Reza Soltanghoraee, Haleh Akhondi, Mohammad Mehdi Tarahomi, Majid Jeddi-Tehrani, Mahmood Rabbani, Hodjattallah |
author_facet | Hemmati, Shayda Zarnani, Amir Hassan Mahmoudi, Ahmad Reza Sadeghi, Mohammad-Reza Soltanghoraee, Haleh Akhondi, Mohammad Mehdi Tarahomi, Majid Jeddi-Tehrani, Mahmood Rabbani, Hodjattallah |
author_sort | Hemmati, Shayda |
collection | PubMed |
description | Gene expression profiling of ovarian carcinoma tissues has shown an increase of four-fold expression of SORT1 gene. Sortilin 1 (NTR-3) is a 95–100 kDa protein normally expressed in heart, brain, placenta, skeletal muscle, spinal cord, thyroid, and testis. However, its expression has never been reported in normal ovary. Here, we report expression of sortilin 1 in ovarian carcinoma tissues both at gene and protein levels. Sortilin 1 was expressed in all ovarian carcinoma patients (n=15) as well as ovarian carcinoma cell lines (n=5) regardless of their phenotypic characteristics. Non-malignant ovaries (n=6) did not express sortilin 1. The molecular basis for this ectopic expression is not yet clear. Our results showed a major cell surface expression of sortilin 1 rather than ER-Golgi compartment where it is mainly expressed. This finding may introduce sortilin 1 as a novel tumor marker for diagnosis of ovarian carcinoma and may signify its therapeutic value in targeted therapy. |
format | Online Article Text |
id | pubmed-3558127 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Avicenna Research Institute |
record_format | MEDLINE/PubMed |
spelling | pubmed-35581272013-02-13 Ectopic Expression of Sortilin 1 (NTR-3) in Patients with Ovarian Carcinoma Hemmati, Shayda Zarnani, Amir Hassan Mahmoudi, Ahmad Reza Sadeghi, Mohammad-Reza Soltanghoraee, Haleh Akhondi, Mohammad Mehdi Tarahomi, Majid Jeddi-Tehrani, Mahmood Rabbani, Hodjattallah Avicenna J Med Biotechnol Original Article Gene expression profiling of ovarian carcinoma tissues has shown an increase of four-fold expression of SORT1 gene. Sortilin 1 (NTR-3) is a 95–100 kDa protein normally expressed in heart, brain, placenta, skeletal muscle, spinal cord, thyroid, and testis. However, its expression has never been reported in normal ovary. Here, we report expression of sortilin 1 in ovarian carcinoma tissues both at gene and protein levels. Sortilin 1 was expressed in all ovarian carcinoma patients (n=15) as well as ovarian carcinoma cell lines (n=5) regardless of their phenotypic characteristics. Non-malignant ovaries (n=6) did not express sortilin 1. The molecular basis for this ectopic expression is not yet clear. Our results showed a major cell surface expression of sortilin 1 rather than ER-Golgi compartment where it is mainly expressed. This finding may introduce sortilin 1 as a novel tumor marker for diagnosis of ovarian carcinoma and may signify its therapeutic value in targeted therapy. Avicenna Research Institute 2009 /pmc/articles/PMC3558127/ /pubmed/23407681 Text en Copyright © 2009 Avicenna Research Institute http://creativecommons.org/licenses/by-nc/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly. |
spellingShingle | Original Article Hemmati, Shayda Zarnani, Amir Hassan Mahmoudi, Ahmad Reza Sadeghi, Mohammad-Reza Soltanghoraee, Haleh Akhondi, Mohammad Mehdi Tarahomi, Majid Jeddi-Tehrani, Mahmood Rabbani, Hodjattallah Ectopic Expression of Sortilin 1 (NTR-3) in Patients with Ovarian Carcinoma |
title | Ectopic Expression of Sortilin 1 (NTR-3) in Patients with Ovarian Carcinoma |
title_full | Ectopic Expression of Sortilin 1 (NTR-3) in Patients with Ovarian Carcinoma |
title_fullStr | Ectopic Expression of Sortilin 1 (NTR-3) in Patients with Ovarian Carcinoma |
title_full_unstemmed | Ectopic Expression of Sortilin 1 (NTR-3) in Patients with Ovarian Carcinoma |
title_short | Ectopic Expression of Sortilin 1 (NTR-3) in Patients with Ovarian Carcinoma |
title_sort | ectopic expression of sortilin 1 (ntr-3) in patients with ovarian carcinoma |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3558127/ https://www.ncbi.nlm.nih.gov/pubmed/23407681 |
work_keys_str_mv | AT hemmatishayda ectopicexpressionofsortilin1ntr3inpatientswithovariancarcinoma AT zarnaniamirhassan ectopicexpressionofsortilin1ntr3inpatientswithovariancarcinoma AT mahmoudiahmadreza ectopicexpressionofsortilin1ntr3inpatientswithovariancarcinoma AT sadeghimohammadreza ectopicexpressionofsortilin1ntr3inpatientswithovariancarcinoma AT soltanghoraeehaleh ectopicexpressionofsortilin1ntr3inpatientswithovariancarcinoma AT akhondimohammadmehdi ectopicexpressionofsortilin1ntr3inpatientswithovariancarcinoma AT tarahomimajid ectopicexpressionofsortilin1ntr3inpatientswithovariancarcinoma AT jedditehranimahmood ectopicexpressionofsortilin1ntr3inpatientswithovariancarcinoma AT rabbanihodjattallah ectopicexpressionofsortilin1ntr3inpatientswithovariancarcinoma |